Nerviano Medical Sciences S.r.l. to present data on its platform of payload linkers for ADC conjugation at the World ADC Summit 2024 in London, UK (March 12th-15th, 2024)
March 8, 2024

Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2024 summit that will be held in London, UK (World ADC Europe) from March 12th to March 15th, 2024, with a poster presentation entitled:

A payload-linker generating machine to quickly move from small molecules to characterized tool ADCs and PDCs

NMS, leveraging on its proprietary chemical collection and applying a rigorous screening funnel, generated a portfolio of characterized payload linkers with diversified MoAs to target different tumor types.

Pillars of available technology are: 1) NMS-P945, a ‘plug-and-play’ thienoduocarmycin, active in chemoresistant cells, showing bystander effect and immunogenic cell death properties, highly efficacious in vivo in preclinical models and greater nonclinical safety profile, 2) next generation anthracycline payload linkers with improved stability and safety profile, both DNA damaging agents, 3) novel payloads.

NMS seek for collaborations with partners having an established expertise in biologics to launch new innovative projects.


Welcome and Check out our new motion picture!